Cancer Network | Cervical Cancer
49 FOLLOWERS
The ModernMedicine Network brings together news, content, tools, and learning programs from credited, trusted information sources. Curated by a leading group of advisors, consultants, key opinion leaders, and content affiliates, ModernMedicine is a news hub for health industry professionals.
Cancer Network | Cervical Cancer
1M ago
Treatment with pembrolizumab plus chemotherapy with or without bevacizumab yields an overall survival improvement regardless of squamous or nonsquamous cervical cancer histology ..read more
Cancer Network | Cervical Cancer
1M ago
Study finds social determinants of health linked to variations in cervical cancer rates ..read more
Cancer Network | Cervical Cancer
1M ago
Treatment with simple hysterectomy reduces the incidence of urinary incontinence compared with radical hysterectomy in patients with low-risk cervical cancer ..read more
Cancer Network | Cervical Cancer
2M ago
Durvalumab Plus CRT Fails to Meet PFS End Point in High-Risk Locally Advanced Cervical Cancer Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research. Lead Investigator of SKYSCRAPER-04 Notes No Statistical Significance in Cervical Cancer Jyoti S. Mayadev, MD, Discusses Rationale for Assessing Durvalumab/CRT Vs Placebo/CRT in High-Risk Locally Advanced Cervical Cancer Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care? Medical Cross ..read more
Cancer Network | Cervical Cancer
3M ago
The FDA has set a Prescription Drug User Fee Act date of May 9, 2024 for the potential full approval of tisotumab vedotin for those with recurrent or metastatic cervical cancer ..read more
Cancer Network | Cervical Cancer
3M ago
Findings from the phase 3 KEYNOTE-A18 trial support the FDA approval of pembrolizumab plus external beam radiotherapy and concurrent chemotherapy in stage III to IVA cervical cancer ..read more
Cancer Network | Cervical Cancer
4M ago
Investigators note a trend towards improved overall survival with cadonilimab plus chemotherapy with or without bevacizumab among those with cervical cancer in the phase 3 AK104-303 trial ..read more
Cancer Network | Cervical Cancer
5M ago
Combining atezolizumab with bevacizumab and chemotherapy may be a new frontline therapy option for patients with metastatic, persistent or recurrent cervical cancer, says Ana Oaknin, MD, PhD ..read more
Cancer Network | Cervical Cancer
5M ago
Progression-free survival benefit appears consistent in patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin ..read more